☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
pegfilgrastim
Real-World Study Demonstrated Economic Benefits of Pegfilgrastim Biosimilar for the Prevention of Febrile Neutropenia
April 18, 2022
Sandoz Receives Health Canada's Approval to Launch Ziextenzo (biosimilar- pegfilgrastim) and Riximyo (biosimilar- rituximab) in Ca...
June 10, 2020
Insights+ Key Biosimilars Events of May 2020
June 5, 2020
Sandoz's Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration of Neutropenia
November 27, 2018
Load more...
Back to Home
